BEAM
Beam Therapeutics
NASDAQ: BEAM · Cambridge, MA · Healthcare
$30.69-0.50 (-1.60%)Closed
Market Cap$2.84B
Cash$978.0Mmost recent
Runway30 mo$98.0M Q burn
P/E (TTM)—EPS $-4.65
52-Wk Range$15.83 – $35.41
Avg Volume2.2M3-month
Healthstable
Base-editing company developing precision genetic medicines for sickle cell disease, oncology, and inherited metabolic disorders.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$30.69+27.3%
Pipeline
Drug candidates sponsored by Beam Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 1 | BEAM-201 | Lymphoblastic Lymphoma+2 more | Active, not recruiting | 2026-12 | 1 | |
| Phase 1 | BEAM-301: Single dose of BEAM-301 administered by IV | Glycogen Storage Disease Type Ia | Recruiting | 2027-12-30 | 1 | |
| Phase 1 | BEAM-101 | Sickle Cell Disease | Active, not recruiting | 2028-02 | 1 | |
| Phase 1 | BEAM-302 | Alpha 1-Antitrypsin Deficiency | Recruiting | 2028-05 | 1 | |
| Phase 1 | BEAM-103 | Healthy Subjects+1 more | Recruiting | 2026-01-29past | 1 | |
| N/A | Long-Term Follow-up Study of patients who received BEAM-101 | Hemoglobinopathy+1 more | Recruiting | 2043-02-12 | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Gene editing · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.